IER5, an immediate early response gene, plays diverse roles in cell cycle regulation, response to irradiation, and DNA damage response [2,3,4]. It is involved in pathways such as Notch signaling and interacts with proteins like PP2A/B55α, HSF1, and PARP1 [1,4,7,8]. IER5 is associated with multiple biological processes and has implications in various diseases, making it an important gene for study [2,5,6].

In glioma patients, high IER5 gene expression is linked to poor prognosis, with significant correlations to WHO grade, IDH status, epidermal growth factor receptor status, age, and histological type [2]. In ovarian cancer, IER5 promotes cell proliferation and peritoneal dissemination, and higher expression of IER5 family genes is related to poorer prognosis [5]. In human hepatocellular carcinoma cells, overexpression of IER5 inhibits cell growth and enhances apoptosis induced by radiation or cisplatin [6]. In Hela cells, interference with IER5 expression decreases the efficiency of DNA double-strand breaks repair [8].

In conclusion, IER5 is crucial in multiple biological processes and disease conditions. Its role in promoting tumor progression in glioma and ovarian cancer, as well as its impact on apoptosis in hepatocellular carcinoma and DNA repair in Hela cells, highlights its significance in understanding disease mechanisms. Further study of IER5, potentially through gene knockout models in the future, may provide more insights into these processes and offer new therapeutic strategies.